Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims focus on a three-gene biomarker signature involving elevated expression of PTGR1, PTPN14, and ASPH to identify patients who may benefit from treatment.
The patent allowance underscores the role of Lantern's RADR artificial intelligence platform, which helped identify the biomarker signature used in the patent. This supports the development of a precision medicine approach for LP-184, potentially improving treatment outcomes by targeting patients most likely to respond. In its Phase 1a trial, Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This development matters because it highlights the shift toward biomarker-driven cancer therapies, which can enhance efficacy and reduce unnecessary side effects. By using a specific genetic signature, Lantern aims to match LP-184 with patients who have the highest probability of response, potentially improving clinical outcomes and accelerating drug development. For investors and the industry, the patent allowance strengthens Lantern's IP position and validates its AI-driven approach to drug discovery.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. Additionally, Lantern's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more information on Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN. To view the full press release, visit https://ibn.fm/LRGUo.
